Publication number: 20230020548
Abstract: This disclosure relates to use of anti-IL-1? antibodies (e.g., canakinumab or gevokizumab) in a therapy treating, preventing, reducing, or alleviating one or more manifestations and complications in individuals suffering from sickle cell disease (including, e.g., homozygous HbS gene carriers, heterozygotes with sickle-beta-thalassemia with an SCD supporting combination of HbS gene and beta-tha1 gene, an individual with one sickle cell gene and one null allele, or an individual with hemoglobin sickle cell disease), optionally in combination with an additional therapeutic agent. Such manifestations and complications include, but are not limited to: pain, fatigue, hospitalization, poor sleep quality, work or school absences, narcotic use, acute or chronic blood transfusion therapy, acute chest syndrome, bone infarct, avascular necrosis, osteonecrosis, stroke, priapism, infarction of penis, a cardiovascular disorder, growth delay, stunted growth, low body mass index (BMI), low body weight, and organ damage.
Type:
Application
Filed:
October 26, 2020
Publication date:
January 19, 2023
Inventors:
Alexandre Yann Guichard, Jiri Kovarik, Yue Li, Elizabeth Akselrod McNamara, Karin Sigrid Meiser, Stephen John Oliver, Michael Shi